Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's mislabeled on the OTC Disclosure & News as a Q but is actually amendment of the 2022 Annual Report. There is no mention of the separate 2022 audited fins previously prepared by Blaze Gries, CPA. (Yes, I'm aware he reportedly sold his practice and maybe went BK, but I haven't seen a recission of his audit report.) JMHO.
At the top of the amended report, it says the amendment is to recognize Series F Preferred shares subscribed sometime in 2022. See pages FS-43 and 44. It appears that Series E and F are sometimes used interchangeably, making for some confusion. They used Series E Preferred in 2021 and 2022 to raise $1 million for 2.5 million shares each year. Why use Series F's now? JMHO.
I suggest reviewing the signature blocks on pages FS-26 and 27. Supposedly, CC signed this report. I wonder if he knows. JMHO.
He did several amendments to substantive decisions made w/o common shareholder vote.
First a Quarterly report isn't audited.
It states that on the filing:
"05/09/2024 Quarterly Report - Amended Unaudited 2022 Annual Report"
"Today they filed a amended 2022 Q thats was audited. Harry must have changed something for his benefit."
IG
There isn’t enough dumping going on for trading club to exit, why they are still around complaining, much less Harry…
Harry is trying to make things seemingly look better on the surface to entice more people to buy to raise the PPS so that Harry can benefit more monies when he dumps more shares into the market.
This has been observed within the last four weeks/ dumping of shares making pps go to trips. He is cashing out his ENZC ATM
Hi' T101..With..1.valid.sentimental'note..Re.all..How.do.you.feel.about.all,of.this
Today they filed a amended 2022 Q thats was audited. Harry must have changed something for his benefit.
Is there still that Friday ihub window where they give all members the ability to use the private messages?
Thanks docsetc, you are the one keeping us informed with facts not regurgitating bs.
FED.........workin 4 the SEC?
Hey Doc, I appreciate all of the DD you have shared. It does appear some of things you indicated have already occurred or will occur are accurate. Could you share how you are obtaining this seemingly inside information?
You have shared information that I have not seen in PRs or filings. I would love to know how I could obtain DD like this.
Please continue to share. In addition if you could provide some type of source that would lend credibility to your info that would be greatly appreciated. I want to believe but the blind faith in this company has not worked out well for me.
This "Show" is about to get a lot better.
Period ended December 31, 2022
The Company issued 50,000,000 shares of common stock from the conversion of 5,000,000 shares of
Series E Preferred.
Note 11. Subsequent Events
After the sale of the operating subsidiaries Virogentics, Inc. and Biogenysis, Inc. to Sagaliam Acquisition
Corp. (SAGA) on September 15, 2023, the Company had no operations and is currently developing a
new business strategy for implementation focused on medical devices and testing.
On January 19, 2024, ENZC and Sagaliam Acquisition Corp (SAGA) agreed it would be mutually
beneficial to Novate the existing Business Combination Agreement and to negotiate a more acceptable
alternative. SAGA believed that there were several unanswered due-diligence questions that arose when
trying to obtain funding for BGEN and BGEN felt SAGA was not providing the funding it needed to
continue. It was therefore decided it was in the best interest of the shareholders of both entities to
negotiate the return of BGEN to ENZC and to renegotiate the purchase price for VIRO to SAGA at a
higher valuation.
In February of 2024 the Company negotiated a reduction in the conversion price of the Series F to
compensate the subscribers for the delay in issuing the Series F Preferred shares purchased in 2022.
On February 22, 2024, ENZC increased the authorized Preferred shares to accommodate the issuance of
the Series F subscribed in November of 2022 and increase the authorized common.
During the negotiations of the concerning the Business Combination Agreement and the reduction in the
conversion price of the Series F a deadlock developed between management preventing a resolution to
be reached between SAGA and ENZC.
On February 26, 2024, the ENZC issued 5,000,000 million shares each to Charles Cotropis, Joseph
Cotorpia and Dr. Gauarv Chandra totaling 15,000,000 common shares. These shares were issued in
place of the stock options issued with the employment contracts entered into with the Officers in
November of 2020 that expired in November of 2023. Harry Zhabilov options were excluded.
On March 19, 2024, at a special-called meeting of the shareholders of the Company, at which a quorum
was present representing excess of 51% of the voting shares of the Company, all Series A shares voted
in favor of electing a new board of directors. The existing board, consisting of Charles Cotropia,
Chairman, and Harry Zhabilov was replaced with Harry Zhabilov, Chairman of the Board, Dr. Lachezar
Ivanov, and Dr. Gaurav Chandra.
At a duly called and noticed Board of Directors meeting held on March 21, 2024, the following new
officers were elected to serve until the next annual (or special called) meeting of the shareholders of the
Company:
President and CEO: Steven Sharabura
CFO and Secretary: Diana Zhabilov
Chief Science Officer: Harry Zhabilov
Dr. Gaurav Chandra was duly noticed, acknowledged notice, and was nominated as an officer. Dr.
Chandra did not attend the meeting and declined the position. As of the date of the meeting, Dr. Chandra
remained a director elect of the Company.52
Got your msg. Appreciate the work you’ve put in here!
Guess that’s why the recombant Clone (whatever number it is) never had any real progress or updates for us all that time. Bc ITV1 was garbage. The combo therapy was the whole point of the merger in 2020, so I guess once they found out ITV1 was junk, that was the beginning of the end here considering all the problems that came with working with Harry in the first place.
I’ll admit, I never saw the “we’re switching gears from medical cures to selling bedpans” 180 coming. Even with the warning of “no assets, no operations” since last summer, I didn’t see them throwing in the towel like this. This is pretty much like most otcs now, next to no real value and empty promises of all these things they’re going to be working on that never really go anywhere.
That's Zhabilov's and Sharabura's plan. I don't think they'll even get that tunnel's exit.
And I think Harry is ready to sell off whatever meager value ITV-1 has left to it. If failed some of the toxicology tests, and they have no answer for that to date. Also, having the MM's sell off and pick up more of the cheap super-diluted shares is making him just enough to live off of, but I'd expect a bankruptcy notice long before a new product sale.
Boot the bums to the curve. Let the adults back in to run the show.
GLTY
With the new info at hand, I completely agree Wick. Just hope it's not a well-orchestrated pie story by the CCC group.
I do have some faith remaining in them.
GLTY
Man, quite telling, if you read between the lines. Harry squeezed out the CCC group, wanted Chandra in only for their IPs, and diluted the commons into oblivion, where we're currently at now. All of that page 52 can occur without a dollar changing hands as well.
And there's no money coming in from SAGA, anyone want to debate that?
Looks like Harry was more concerned about control and exposure and did a BS Preferred-2-Commons conversion to say he gave the CCC group their value back in stock, took options off the table, and slipped out the back door, which he's locked behind now.
If Sharabura's not looking for another opportunity elsewhere right now, he's even dumber than his resume shows.
Page 52 and the rest of the report selectively omits, it seems, any operational funds on-hand, if any, and any set revenue plans to keep ENZC in operation. A paper tiger trying to land a contract before having anything of value to deliver. ITV-1 has failed, IPF-Immune is a joke, and those energy shots on the VIRO website are at the non-inventory, bottom rung of a huge, competitive market.
ENZC and VIRO have nothing current day. What will SAGA ever be paying for, (?) What lawyer will even bother drafting up that FINRA?
This is less than vapor. Let's hope Chandra's efforts and Charles initiatives prove fruitful.
GLTA
up 16% on low volume, MMs probably spoofing lol, the beginning of the end of a stock's price action, final days are near
docsetc, I believe it is in the best interests of the shareholders to separate from the Zhabilovs. If given the opportunity, I would consider backing the Cotropias in their future endeavors. It will be interesting to see how this mess gets sorted out…,
Love to steal Harry's current hip joints, let him crawl around sub-penny like our current PPS....
Most likely. Could have a bonfire with the old IPF-Immune supply, no one reports a benefit from it.
Not sure about that, but this one in Houston was the one they were referring too. Not that far from you. Over in the Brookhollow area, off US 290 and Loop 610. A straight shot route up 290 from Cypress.
Shouldn’t have come as a surprise to anyone. They told us “no operations” would be the outcome last July. “No assets, no operations”. Some of us discussed and warned about it repeatedly and were called bashers for it.
Couldn't be more clearer "After the sale of the operating subsidiaries Virogentics, Inc. and Biogenysis, Inc. to Sagaliam Acquisition
Corp. (SAGA) on September 15, 2023, the Company had no operations and is currently developing a
new business strategy for implementation focused on medical devices and testing. "
$ENZC AMENDED ANNUAL Statement filed yesterday (Period ending 12/31/23), end of year again. Appears to be setting up to at least get back to Pink Current.
--
Lets see, ONE HAS TO READ PAGE 52 of Subsequent events and the STORY THERE
--
here you go Full Disclosure Amended
https://www.otcmarkets.com/otcapi/company/financial-report/401387/content
--
Page 52 is A MUST READ FOR ALL !
We’ve gone from curing HIV, monoclonal antibodies to selling used pacemakers.
Great accomplishment!
I tought Amazon had several "Third Coast Fulfillment Centers" across the U.S.
Hilarious! Sounds like a thought in the infamous Harry’s head is a contract with unbeknownst third parties.
docsetc, Maybe Harry can sell used hip replacement joints that are recovered from cremated bodies.
And, yes, I HAVE started happy hour!
PS: "Third Coast Fulfillment" is right here in Houston, Texas. It's an old, but large warehousing company where 3rd party companies rent space for the product they wish to sell and distribute. It's warehouse space with shipping services, nothing more. The marketing company formed to work with them, is completely unknown to Third Coast Fulfillment, I asked them. Seems 'Enzolytics' might be a prospective new customer of theirs, but they've heard nothing about a marketing contact.
Next Zhabilov Post: "Enzolytics announces a partnership with ACME Pacemakers, a used cardiology hardware company for seeking out new market intiatives, for dead-battery pacemakers harvested out of former customer cadavers."
Nope, I have not started happy hour today...yet.
BGEN's website has been taken down. VIRO's website is just a dead, 3-page hack-sale site now, good luck getting that useless product if you buy it, and ENZC's website has no changes for many, many months now.
Harry Zhabilov: Grave-Digger.
Sharabura is still scrambling to sell used medical devices, and won't return communications, the investor boards for ENZC have run silent. Stock sits semi-cold for now, after an 11-million share activity day.
The CCC clan needs to keep the road burning forward.
EOM
Thats most otc stocks imo. You mean IGPK isn’t going to the moon? It’s different of course…and so is the next one and the next one …. 😂
Nasdaq dealt with SAGA when it was delisted - that meant the SAGA fake deal was really dead.
"The three of them as previous owners of ENZC may have already gone to the SEC filed a complaint , laid out all the facts about SAGA and the SEC could already be investigating the SPAC and what a few of us have been saying it was not legal due to the expiration of the by laws of the SPAC and their own lawyer stating they didnt file on time nor paid the required deposit."
What part of the ENZC insiders being part of the fake SAGA deal don't you understand.
The SAGA deal was for pumping purposes only.
So you actually believed that SAGA was going to acquire 2 empty worthless shells for $450M. SMH!
With the history of the ENZC insiders scamming they don't want any part of the SEC. I suggest you read the ENZC history of press releases.
IG
I think I gave a fair and even analysis. The first time Chandra said groundbreaking and it was fluff I sold most. Everyone called me crazy and I was even doxxed. He hasn't put up for over 3 years after all the big talk. Looks sketchy as hell.
There isn't a Clone 3 patent - the insiders control the vote - retail shareholders have to sit and watch their investment disappear.
Do you guys ever do any research?
"Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
InventorJoseph P. Cotropia
Current Assignee BIO CLONETICS BIOCLONETICS IMMUNOTHERAPEUTICS Inc
Application US07/633,964 events
1990-12-26
Application filed by Bioclonetics Inc
1990-12-26
Priority to US07/633,964
1995-10-17
Publication of US5459060A
1995-10-17
Application granted
Anticipated expiration 2012-10-17
Status. Expired - Lifetime"
"Abstract
Disclosed is a human monoclonal antibody produced by the hybridoma designated Clone 3 and having A.T.C.C. Accession No. CRL 10198."
The Clone 3 patent didn't have any commercial value.
Then we have:
"A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
J Cotropia et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul.
Abstract
A potential component that may be useful for passive immunotherapy for HIV-1 is human monoclonal antibodies (HumAbs) possessing potent anti-HIV-1 activity that is directed against conserved regions of the envelope glycoprotein. Such antibodies would, in principle, have the ability to neutralize diverse isolates of HIV-1...
Therefore, clone 3 reactivity defines a conserved neutralizable site on the HIV-1 transmembrane glycoprotein. Clone 3 and the conserved immunogenic epitope on gp41 could be useful in passive and active immunotherapy for the acquired immunodeficiency syndrome (AIDS)."
Clone 3 has been pumped since at least 1990.
ENZC has nothing of value.
IG
It is difficult to believe that anyone ever thought the SAGA deal was real.
1. Just research Barry Kostiner - you can't blindly believe the company hype without verifying everything.
2. Cotropia was involved in the SAGA scam.
3. As a investor you have to use logic instead of greed - no one would pay $250M for Virogentics and Biogenysis - they don't own anything of value. But when in a couple of weeks SAGA magically increased the price to $450M - and most believed that nonsense.
4. There were only 2 patents that are worthless and both were assigned to the The Zhabilov Trust - so ENZC doesn't own any patents.
5. When ENZC never applied to do FDA approved clinical trials - most didn't understand that a drug patent without passing FDA clinical trials is worthless. This was a tell.
6. If ENZC was a real company they would have filed a Registration statement and become a SEC reporter. Here is a hint for the future - if a OTC company doesn't report to the SEC it is a guaranteed scam.
7. Chandra wasn't smart enough or have the technical background to build any kind of AI for drug development - just look at the financials there wasn't enough capital to do what was pumped.
8. Investors should have been suspicious when the clinical trials was in Africa and Bulgaria and they never published anything in a peer reviewed journal.
9. There was never a chance for a buyout - ENZC didn't have anything that a real pharmaceutical company wanted or needed. Some were posting that ENZC had a cure for Covid, HIV-AIDS etc and that Cotropia has successfully filed a lawsuit against Fauci and none of it was true - but many believed.
These scam shells are passed around and someone will come in and attempt to pump it and giddiness will begin.
ENZC is and always was a share selling scheme.
IG
You are right the worst investment strategy for the OTC is averaging down but the scammers love it.
IG
Can't deny what you're saying, as enough of the details are not available yet. I think the company was too segregated and working in remote spheres, not watching all things at all times. Zhabilov screwed over a lot. and yes, perhaps the rest of the officers should have bolted or acted earlier, but I think the false promises of the SAGA deal dragged the entire company down the drain.
We'll see.
GLTY
So why do you believe the "CCC" allowed all of this egregiously damaging behavior to occur? Whether they see it or not, the "CCC" own the history as well b/c their posteriors were in exec mgmt chairs. And why would Chandra speak with folks "off the record", further damaging the little trust some of us have left? I'd love nothing more than to witness the cleaning-up of Enzolytics and the bloody end of the little company shell game mess.
What theories do you have? Oh yeah that's right . We know how you did the past 3 years lmao
Same old faithful crowd keeps on *averaging down* and loading enzc, absolutely strange behavior, the cultish love that has occured here is something to study one day. Never has a stock been able to produce nothing, outright lie to you for years on end, and *investors* continue to pour all their money into it blindly and demand 0 accoutability, just strange.
Followers
|
1245
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
200049
|
Created
|
01/07/10
|
Type
|
Free
|
Moderators Homebrew Timing101 archilles SeniorApollo |
Independent Valuation Report Pre Clinical Studies
Investments
___________________________________________________________________________________
Press Release July 20-2021
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc.
for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
https://www.creative-biolabs.com/
https://finance.yahoo.com/news/enzolytics-announces-signing-letter-intent-113000339.htm
________________________________________
Press release July 21-2021
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and
Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
https://www.lonza.com/
https://www.bloomberg.com/press-releases/2021-07-21/enzolytics-and-lonza-bioscience-combine-technologies-to-fast-track-development-and-production-of-anti-hiv-and-anti-sar
_________________________________________
July 22 INTERVIEW
with
James Hicks, Charles Cotropia and Gurav Chandra
http://www.youtube.com/watch?v=mdljO9VLgj0
______________________________________________________________
COLLEGE STATION, TX August 25, 2021
Important Excerpt from this news progress update.
>>>>>><<<<<<
"The monoclonal antibodies being produced by Enzolytics against the CoronaVirus target 19 conserved immutable sites on the virus, sites which the Company has now confirmed are conserved sites not only on the initial virus strains but also existing in the Delta and Lambda variants, as well as in the Alpha, Beta and Gamma variants."
Enzolytics Inc. and Samsung Biologics Announce
Development and Manufacturing Agreement for Anti-
HIV and Anti-SARS-CoV-2
Important Excerpt from this news progress update.
>>>>>><<<<<<
"Samsung Biologics (KRX: 207940. K.S.), a leading contract development and manufacturing organization and Enzolytics (ENZC), a drug development company committed to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases, announced the signing of a strategic CDMO partnership agreement."_______
2000 North Central Expressway
Plano, TX 75074
972-292-9414
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |